NZ200247A - Calcium oxaprozin - Google Patents

Calcium oxaprozin

Info

Publication number
NZ200247A
NZ200247A NZ200247A NZ20024782A NZ200247A NZ 200247 A NZ200247 A NZ 200247A NZ 200247 A NZ200247 A NZ 200247A NZ 20024782 A NZ20024782 A NZ 20024782A NZ 200247 A NZ200247 A NZ 200247A
Authority
NZ
New Zealand
Prior art keywords
oxaprozin
calcium
pharmaceutical formulation
calcium oxaprozin
agent
Prior art date
Application number
NZ200247A
Other languages
English (en)
Inventor
A S Mughal
Original Assignee
Wyeth John & Brother Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth John & Brother Ltd filed Critical Wyeth John & Brother Ltd
Publication of NZ200247A publication Critical patent/NZ200247A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NZ200247A 1981-04-28 1982-04-06 Calcium oxaprozin NZ200247A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB8113074 1981-04-28

Publications (1)

Publication Number Publication Date
NZ200247A true NZ200247A (en) 1984-10-19

Family

ID=10521427

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ200247A NZ200247A (en) 1981-04-28 1982-04-06 Calcium oxaprozin

Country Status (24)

Country Link
US (2) US4465838A (en:Method)
EP (1) EP0063884B1 (en:Method)
JP (1) JPS57181072A (en:Method)
KR (1) KR880000871B1 (en:Method)
AT (1) ATE14015T1 (en:Method)
AU (1) AU544975B2 (en:Method)
CA (1) CA1169867A (en:Method)
CS (1) CS236674B2 (en:Method)
DD (1) DD202017A5 (en:Method)
DE (1) DE3264400D1 (en:Method)
DK (1) DK150604C (en:Method)
ES (1) ES511730A0 (en:Method)
FI (1) FI71314C (en:Method)
GR (1) GR75913B (en:Method)
HU (1) HU185276B (en:Method)
IE (1) IE52909B1 (en:Method)
IL (1) IL65443A (en:Method)
MY (1) MY8700599A (en:Method)
NZ (1) NZ200247A (en:Method)
PH (1) PH18053A (en:Method)
PL (1) PL136322B1 (en:Method)
PT (1) PT74794B (en:Method)
ZA (1) ZA822355B (en:Method)
ZW (1) ZW7482A1 (en:Method)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5380738A (en) * 1993-05-21 1995-01-10 Monsanto Company 2-substituted oxazoles further substituted by 4-fluorophenyl and 4-methylsulfonylphenyl as antiinflammatory agents
US6726928B2 (en) * 1994-10-28 2004-04-27 R.P. Scherer Technologies, Inc. Process for preparing solid dosage forms for unpalatable pharmaceuticals
DE69733752T2 (de) * 1996-05-20 2006-06-01 G.D. Searle Llc, Chicago Arzneimittel enthaltend oxaprozin-natriumsalz,-kaliumsalz, oder-tris(hydroxymethyl)aminomethansalz
US7358254B2 (en) * 2001-07-13 2008-04-15 Bristol-Myers Squibb Company Method for treating atherosclerosis employing an aP2 inhibitor and combination
AU2006228869A1 (en) * 2005-03-30 2006-10-05 Astion Pharma A/S Oxaprozin or a closely related compound for the treatment of eczema
UY29449A1 (es) * 2005-03-30 2006-10-02 Astion Dev As Tratamiento de enfermedades dermatólogicas y del prurito.
US9890339B2 (en) * 2008-08-26 2018-02-13 Dorf Ketal Chemicals (I) Private Limited Additive for inhibiting acid corrosion and method of using the new additive
KR20140065862A (ko) * 2012-11-22 2014-05-30 에스케이케미칼주식회사 발포성 속붕해성 이매티닙 제제

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1206403A (en) * 1966-12-15 1970-09-23 Wyeth John & Brother Ltd Oxazoles
GB1245087A (en) * 1967-10-26 1971-09-02 Wyeth John & Brother Ltd Heterocyclic compounds
US3578671A (en) * 1967-11-06 1971-05-11 Wyeth John & Brother Ltd Oxazoles

Also Published As

Publication number Publication date
EP0063884B1 (en) 1985-06-26
IL65443A (en) 1985-04-30
PL136322B1 (en) 1986-02-28
DE3264400D1 (en) 1985-08-01
US4465838A (en) 1984-08-14
HU185276B (en) 1984-12-28
FI821324A0 (fi) 1982-04-15
FI821324L (fi) 1982-10-29
PT74794B (en) 1983-11-07
KR830009772A (ko) 1983-12-23
DK150604B (da) 1987-04-13
JPH0261466B2 (en:Method) 1990-12-20
MY8700599A (en) 1987-12-31
CS236674B2 (en) 1985-05-15
AU8237882A (en) 1982-11-04
KR880000871B1 (ko) 1988-05-28
US4532253A (en) 1985-07-30
PT74794A (en) 1982-05-01
DK183582A (da) 1982-10-29
FI71314C (fi) 1986-12-19
IE820766L (en) 1982-10-28
FI71314B (fi) 1986-09-09
DD202017A5 (de) 1983-08-24
IL65443A0 (en) 1982-07-30
GR75913B (en:Method) 1984-08-02
IE52909B1 (en) 1988-04-13
PL236145A1 (en:Method) 1982-12-06
ES8307230A1 (es) 1983-07-01
DK150604C (da) 1987-12-07
AU544975B2 (en) 1985-06-27
ES511730A0 (es) 1983-07-01
ZA822355B (en) 1983-11-30
CA1169867A (en) 1984-06-26
JPS57181072A (en) 1982-11-08
EP0063884A1 (en) 1982-11-03
ZW7482A1 (en) 1983-11-09
ATE14015T1 (de) 1985-07-15
PH18053A (en) 1985-03-18

Similar Documents

Publication Publication Date Title
EP1622586B1 (en) Process for preparing tannate tablet capsule or other solid dosage forms
HU195617B (en) Process for producing pharmaceutical compositions containing 2-/4-isobutyl-phenyl6-propionic acid
IE880584L (en) Pharmaceutical tablet, pharmaceutical granulate and process¹for their preparation
NZ229064A (en) Resin adsorbates comprising ranitidine/synthetic cation exchange resin complex; pharmaceutical compositions
IE890545L (en) Pharmaceutical granulate
KR0177493B1 (ko) 단사정계 결정구조를 갖고 감열, 감광 및 감습성이 있는 활성성분을 함유하는 정제의 제조방법
US4465838A (en) Oxaprozin calcium salt
CZ300908B6 (cs) Tableta obsahující levothyroxin natrium a zpusob její výroby
JPH10147524A (ja) フォルスコリン誘導体含有経口製剤及び医薬製剤の製法
EP0380021B1 (en) Stabilizing system for solid dosage forms
KR20030024833A (ko) 시탈로프람을 함유하는 약학 조성물
JPH0774153B2 (ja) ロキソプロフェン・ナトリウム含有製剤
CA2452386A1 (en) Granulates containing liposoluble substances and a process for the preparation thereof
KR100515201B1 (ko) 라세미화반응에대하여안정화된실란세트론제제
GB1582162A (en) Stable prostaglandin composition and process for the preparation thereof
GB2097389A (en) Oxazole derivative
JPH0344052B2 (en:Method)
US2768115A (en) Penicillin-aspirin tablets
JP2669517B2 (ja) ロキソプロフェン・ナトリウム含有固形製剤
GB2148894A (en) Aluminium salts of oxazole derivatives
JPH08325142A (ja) ヨウ化イソプロパミド含有製剤
CZ57793A3 (en) Hard capsules of cytarabia-ocphosphate
JPS60255724A (ja) ニフエジピン配合調製物
GB1575978A (en) Solid choline salicylate compositions
JP2000169367A (ja) メキタジン含有内服固形製剤